Experimental drug tested to slow scarring lung disease

This study tested whether an oral drug called MN-001 could help control idiopathic pulmonary fibrosis (IPF), a serious disease that scars the lungs. Fifteen adults with moderate to severe IPF took either MN-001 or a placebo pill twice daily for six months, followed by another six months where everyone received the drug. Researchers measured changes in lung function, breathing difficulty, and quality of life to see if the treatment was safe and effective.